|
gptkbp:instanceOf
|
gptkb:drug
gptkb:acetylcholinesterase_inhibitor
|
|
gptkbp:ATCCode
|
gptkb:N07AA01
|
|
gptkbp:CASNumber
|
gptkb:59-99-4
|
|
gptkbp:chemicalFormula
|
C12H19N2O2
|
|
gptkbp:contraindication
|
urinary tract obstruction
mechanical intestinal obstruction
|
|
gptkbp:discoveredBy
|
gptkb:Mary_Walker
|
|
gptkbp:discoveredIn
|
1931
|
|
gptkbp:eliminationHalfLife
|
50–90 minutes
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
neostigmine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits acetylcholinesterase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
intramuscular
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
nausea
vomiting
bradycardia
abdominal cramps
increased salivation
|
|
gptkbp:synonym
|
gptkb:Neostigmine_bromide
gptkb:Neostigmine_methylsulfate
gptkb:Prostigmin
|
|
gptkbp:usedFor
|
gptkb:myasthenia_gravis
postoperative urinary retention
reversal of non-depolarizing neuromuscular blockade
|
|
gptkbp:bfsParent
|
gptkb:Physostigmine
gptkb:vecuronium
|
|
gptkbp:bfsLayer
|
6
|